Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vixotrigine - Biogen

Drug Profile

Vixotrigine - Biogen

Alternative Names: 1014802; BIIB 074; CNV 1014802; CNV 1014802 A; GSK 1014802 A; GSK1014802; Raxatrigine

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Biogen; GlaxoSmithKline
  • Class Analgesics; Neuropsychotherapeutics; Pyrrolidines; Small molecules
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neuropathic pain; Trigeminal neuralgia

Highest Development Phases

  • Phase III Trigeminal neuralgia
  • Phase II Erythromelalgia; Neuropathic pain
  • Discontinued Bipolar disorders

Most Recent Events

  • 06 Aug 2018 Biogen completes a phase II trial in Neuropathic pain in Austria, Belgium, Bulgaria, Czech Republic, Denmark, England, Estonia, Finland, France, Georgia, Italy, Latvia, Lithuania, Netherlands, Poland, Romania, Scotland, Serbia, Slovakia, Spain, United Kingdom (PO) (NCT02935608; EudraCT2015-004775-78)
  • 24 Jun 2018 Biomarkers information updated
  • 22 Mar 2018 Phase-II clinical trials in Neuropathic pain in Greece, Hungary, Canada (PO) (NCT03339336) (EudraCT2017-000991-27)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top